ALNY — Alnylam Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $32.72bn
- $31.05bn
- $2.25bn
- 84
- 11
- 64
- 53
Annual cashflow statement for Alnylam Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -858 | -853 | -1,131 | -440 | -278 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 221 | 326 | 581 | 480 | 534 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -12.7 | -163 | -35.6 | 10.8 | -214 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -615 | -642 | -541 | 104 | -8.31 |
| Capital Expenditures | -70.4 | -76.4 | -72.1 | -62.2 | -34.3 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -365 | -197 | 241 | -274 | -82.6 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -436 | -273 | 169 | -336 | -117 |
| Financing Cash Flow Items | 495 | 501 | 31 | 24.7 | -8.79 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 995 | 1,247 | 426 | 172 | 294 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -50.6 | 323 | 46.4 | -53.7 | 154 |